This 2-day event to be held on 27-28 November in Brisbane will bring together major national and
international speakers to discuss developments and approaches to treating a range of veterinary species.
Day 1 will have a ‘cutting-edge’ focus, with three international speakers introducing concepts and new
developments across a range of drug groups.
Professor Peter Lees from the Royal Veterinary College has global recognition for his work on
pharmacokinetics and pharmacodynamics across a range of species and, as an ex-editor of the prestigious
Journal of Veterinary Pharmacology and Therapeutics, is well placed to address where veterinary
pharmacology is heading and the use of Pk-Pd interactions to predict drug efficacy.
Chand Khana, Head of the Tumour Metastasis Biology, and Comparative Oncology Section at the US
National Cancer Institute, will talk about drug development projects involving canine patients with cancer,
benefiting both the canine and human species. This new concept is part of the One Medicine research
theme where shared diseases, and shared challenges, see veterinarians working side by side with
biomedical researchers. In the US this has resulted in the Comparative Oncology programme at the NCI
and the Comparative Oncology Consortium consisting of veterinary practices involved in multicentre
therapeutic discovery projects.
Dr Ludovic Pelligand will provide insight to the use of Pk-Pd to ‘customise’ drug prescribing. Professor
Glenn Browning (University of Melbourne) will then provide an update on vaccines and vaccinology, while
Dr Stephen Page will discuss the emerging concerns of antibiotic resistance. A roundtable concludes the
first day, chaired by Professor Gabrielle Cooper (University of Canberra), looking at the pharmacological
implications of challenging cases.
Day 2 will focus on practical applications of therapeutics and will bring together an exciting group of
specialist and expert clinicians, including Fiona Campbell (cardiology), Bob Doneley (avian), Tony Moore
(oncology), Kersti Seksel (behaviour), Amanda Craig (pharmacology), and Paul Mills (pharmacology).
The discipline of pharmacology is one of the most rapidly evolving sciences in the world, as pharmaceutical
companies strive for better approaches to existing and emerging diseases. Veterinary pharmacology is no
exception and the challenge for clinicians is to maintain currency in a constantly expanding field.
The phrase ‘all creatures great and small’ highlights the diversity of veterinary pharmacology, with clinicians
faced daily with the challenge of not only selecting the most appropriate drug, but the correct dose rate,
dose form (i.e., tablet vs. liquid) and duration of treatment.
Every day veterinary clinicians are likely to face wide variation in the characteristics of their patients, at one
extreme elephants and mice but more commonly Chihuahuas and Great Danes, goldfish and parrots. How
can a clinician possibly decide what medicine, what dose, what route of administration, ability of the owner
to treat, and how can response to treatment be successfully monitored? A good grounding in
pharmacology and therapeutics is essential.